N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide | 165669-28-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide
• 英文别名: N-(1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide；4-N-(1H-indol-7-yl)benzene-1,4-disulfonamide
• CAS: 165669-28-3
• 化学式: C₁₄H₁₃N₃O₄S₂
• 分子量: 351.407
• InChiKey: PUPBEGMQWLQKFS-UHFFFAOYSA-N

物化性质

• 熔点：
  218-219 °C(Solv: ethanol (64-17-5); hexane (110-54-3))
• 沸点：
  646.4±65.0 °C(Predicted)
• 密度：
  1.597±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide 在 N-氯代丁二酰亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-[N-(2-氰乙基)-4-[(2,6-二氯-4-硝基苯基)偶氮]苯胺基]乙酸乙酯
  参考文献：
  名称：

  EP1813602

  摘要：

  公开号：
• 作为产物：
  描述：

  7-硝基吲哚-2-甲酸 在 copper(II) oxide 铁粉 、 氯化铵 作用下， 以 喹啉 、 水 、 异丙醇 为溶剂， 反应 13.5h， 生成 N-(1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide
  参考文献：
  名称：

  Benzenesulfonamide derivatives and pharmaceutical composition thereof

  摘要：

  公开号：

  EP2366687B1

文献信息

• Integrin expression inhibitors
  申请人：——

  公开号：US20040018192A1

  公开（公告）日：2004-01-29

  The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

  本发明提供了一种整合素表达抑制剂，以及基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。即提供了一种包含以下式(I)所表示的磺胺化合物、其药理学上可接受的盐或其水合物作为活性成分的整合素表达抑制剂。 在该式中，B表示一个C6-C10芳基环或6-至10成员杂芳基环，可能具有取代基，并且环的一部分可能是饱和的；K表示一个单键，-CH═CH-或-(CR 4b R 5b ) m b -（其中R 4b 和R 5b 相同或不同，各自表示氢原子或C1-C4烷基；m b 表示1或2的整数）；R 1 表示氢原子或C1-C6烷基；Z表示一个单键或-CO-NH-；R表示一个C6-C10芳基环或6-至10成员杂芳基环，可能具有取代基，并且环的一部分可能是饱和的，分别。
• Integrin expression inhibitor
  申请人：Wakabayashi Toshiaki

  公开号：US20050176712A1

  公开（公告）日：2005-08-11

  The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

  本发明提供了一种整合素表达抑制剂，并提供了一种基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。换句话说，本发明提供了一种整合素表达抑制剂，其包括以下式（I）所表示的磺酰胺化合物作为活性成分、其药学上可接受的盐或其水合物： 其中，在上述式中，B表示C6-C10芳基环或6-至10元杂环芳基环，其中可能有取代基，并且环的一部分可能是饱和的；K表示单键，-CH═CH-或-(CR4bR5b)mb-（其中R4b和R5b相同或不同，每个表示氢原子或C1-C4烷基；mb表示1或2的整数）；R1表示氢原子或C1-C6烷基；Z表示单键或-CO-NH-；R分别表示C6-C10芳基环或6-至10元杂环芳基环，其中可能有取代基，并且环的一部分可能是饱和的。
• Composition containing antitumor agent
  申请人：Eisai Co., Ltd.

  公开号：US06060498A1

  公开（公告）日：2000-05-09

  The present invention provides a preparation for injection comprising an antitumor agent which is sparingly soluble in water. Specifically, it provides a composition containing N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide, which contains N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide and a basic substance and will provide an aqueous solution having a pH of 7 or higher when dissolved in water.

  本发明提供了一种注射制剂的制备方法，其中包含一种在水中难溶的抗肿瘤剂。具体而言，它提供了一种含有N-(3-氯-1H-吲哚-7-基)-4-磺酰氨基苯磺酰胺的组合物，该组合物包含N-(3-氯-1H-吲哚-7-基)-4-磺酰氨基苯磺酰胺和一种碱性物质，当溶解在水中时，将提供一个pH值为7或更高的水溶液。
• Crystal of Two-Ring Heterocyclic Sulfonamide Compound
  申请人：Yamamoto Eiichi

  公开号：US20070299266A1

  公开（公告）日：2007-12-27

  Novel β-type crystal of N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide of the formula: characterized in, for example, that in powder X-ray diffractometry, it has a diffraction peak at a diffraction angle (2θ±0.2°) of 18.4°. This crystal has favorable properties, such as high solubility in buffer solutions and various organic solvents, and is suitable to an active ingredient of a pharmaceutical composition for use as an antitumor agent, an activated lymphocyte suppressor or an eating enhancer.

  该式为N-(3-氯-1H-吲哚-7-基)-4-磺酰基苯磺酰胺的小说β型晶体，其特征在于在粉末X射线衍射测量中，在衍射角（2θ±0.2°）为18.4°处具有衍射峰。该晶体具有良好的性质，如在缓冲溶液和各种有机溶剂中具有高溶解度，并适用于作为抗肿瘤剂、激活淋巴细胞抑制剂或增食剂的制药组合物的活性成分。
• INTEGRIN EXPRESSION INHIBITOR
  申请人：WAKABAYASHI Toshiaki

  公开号：US20100267754A1

  公开（公告）日：2010-10-21

  The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

  本发明提供了一种整合素表达抑制剂，以及一种用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病、抗凝剂或癌症转移抑制剂的药剂，其基于整合素抑制作用。即，提供一种整合素表达抑制剂，其包括以下式（I）所表示的磺酰胺化合物作为活性成分，其药理学上可接受的盐或水合物，其中在该式中，B表示一个C6-C10芳基环或6-到10成员杂环环，可以有取代基，在环中的一部分可能是饱和的；K表示单键，—CH═CH—或—（CR4bR5b）mb—（其中R4b和R5b相同或不同，每个表示氢原子或C1-C4烷基；mb表示1或2的整数）；R1表示氢原子或C1-C6烷基；Z表示单键或—CO—NH—；R分别表示C6-C10芳基环或6-到10成员杂环环，可以有取代基，在环中的一部分可能是饱和的。